← Back to Search

Artificial Intelligence

Automated Screening for Retinopathy of Prematurity

N/A
Waitlist Available
Led By John P Campbell, MD/MPH
Research Sponsored by Siloam Vision
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be younger than 18 years old
Must not have
Admission to a neonatal intensive care unit (NICU) with regressing or treated ROP
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to test a new system called i-ROP DL for screening Retinopathy of Prematurity (ROP) in babies. They will compare the system's accuracy in detecting severe ROP with

Who is the study for?
This trial is for babies born prematurely who are in the NICU and need screening for a serious eye condition called Retinopathy of Prematurity (ROP). The study will use images from previous research to test a new automated system.
What is being tested?
The i-ROP DL system, an automated device designed to detect severe ROP in premature infants using images, is being tested. Its accuracy will be compared with standard image-based diagnoses.
What are the potential side effects?
Since the i-ROP DL system uses existing images for analysis rather than direct physical intervention on patients, there are no direct side effects associated with its use.

Eligibility Criteria

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:
Select...
My baby was in the NICU for retinopathy of prematurity that is getting better or was treated.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
sensitivity and specificity of the i-ROP DL system

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: eROP dataExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

National Eye Institute (NEI)NIH
555 Previous Clinical Trials
1,406,108 Total Patients Enrolled
16 Trials studying Retinopathy of Prematurity
4,658 Patients Enrolled for Retinopathy of Prematurity
Siloam VisionLead Sponsor
1 Previous Clinical Trials
16 Total Patients Enrolled
1 Trials studying Retinopathy of Prematurity
16 Patients Enrolled for Retinopathy of Prematurity
John P Campbell, MD/MPHPrincipal InvestigatorOregon Health and Science University
1 Previous Clinical Trials
16 Total Patients Enrolled
1 Trials studying Retinopathy of Prematurity
16 Patients Enrolled for Retinopathy of Prematurity
~770 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top